Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. [electronic resource]
Producer: 20170724Description: 48-55 p. digitalISSN:- 1473-5687
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- adverse effects
- Carcinoma, Hepatocellular -- drug therapy
- Chi-Square Distribution
- Disease Progression
- Humans
- Kaplan-Meier Estimate
- Liver Neoplasms -- drug therapy
- Logistic Models
- London
- Male
- Middle Aged
- Multivariate Analysis
- Niacinamide -- adverse effects
- Odds Ratio
- Patient Selection
- Phenylurea Compounds -- adverse effects
- Proportional Hazards Models
- Protein Kinase Inhibitors -- adverse effects
- Retrospective Studies
- Risk Factors
- Sorafenib
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.